Benralizumab is already used in the most severe cases, but the latest research suggests it could be used routinely for around two million attacks in the UK each year ...

In five states over nearly a decade, hospitals have increased how frequently they document patients as needing the highest intensity care, which has led to hospitals receiving billions in extra ...

A new injection, benralizumab, outperforms traditional steroids in treating asthma and COPD attacks, reducing treatment ...

With the right training, process, and resources, long term caregivers can confidently treat residents with opioid use ...

Several adverse health outcomes are associated with AD, such as atopic and allergic conditions, immune mediated conditions, and more.

Discover how metabolic syndrome raises COPD risk in young adults. Learn about the study linking MetS components to ...

A systematic review reveals chronic pulmonary aspergillosis mortality is driven by age and underlying conditions, ...

Monoclonal antibody benralizumab was found to be more effective than the standard treatment in a clinical trial.

A former employee of a Fort Smith, N.W.T., construction company will spend nearly two years under house arrest and more than ...

Lung Disease Therapeutics Market. The global lung disease therapeutics market is on an impressive growth trajectory, ...

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD ...

Approximately 1 in 20 individuals diagnosed with RSV in outpatient settings were hospitalised within 28 days. Read more.